EA201992646A1 - Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма - Google Patents

Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Info

Publication number
EA201992646A1
EA201992646A1 EA201992646A EA201992646A EA201992646A1 EA 201992646 A1 EA201992646 A1 EA 201992646A1 EA 201992646 A EA201992646 A EA 201992646A EA 201992646 A EA201992646 A EA 201992646A EA 201992646 A1 EA201992646 A1 EA 201992646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases associated
steroids
therapy
application
treatment
Prior art date
Application number
EA201992646A
Other languages
English (en)
Russian (ru)
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of EA201992646A1 publication Critical patent/EA201992646A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201992646A 2018-11-23 2019-11-22 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма EA201992646A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (1)

Publication Number Publication Date
EA201992646A1 true EA201992646A1 (ru) 2020-05-31

Family

ID=69624712

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992646A EA201992646A1 (ru) 2018-11-23 2019-11-22 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP3884945A4 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN113164464A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4851C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
BR112013020498A2 (pt) * 2011-02-10 2016-08-09 Genqual Corp método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および2−アミノ−2’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEAP202115467A (en) * 2017-09-07 2021-10-11 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Also Published As

Publication number Publication date
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
EP4218758A2 (en) 2023-08-02
PH12021551152A1 (en) 2021-10-25
RU2712281C1 (ru) 2020-01-28
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MX2022013503A (es) 2022-11-16
GEP20237467B (en) 2023-02-10
KR20210095652A (ko) 2021-08-02
ZA202210444B (en) 2023-01-25
MD20210032A2 (ro) 2021-09-30
GEAP202415619A (en) 2024-03-11
EP3884945A1 (en) 2021-09-29
CL2022000683A1 (es) 2022-10-28
IL297533A (en) 2022-12-01
BR112021009801A2 (pt) 2022-03-03
IL283317A (en) 2021-07-29
JP2023015333A (ja) 2023-01-31
GEAP202215712A (en) 2022-10-10
GEP20247643B (en) 2024-07-10
MD20210050A2 (ro) 2021-12-31
MY209416A (en) 2025-07-08
ZA202104247B (en) 2023-03-29
AU2022256212B2 (en) 2024-08-15
AU2019384626A1 (en) 2021-07-15
MX2021006032A (es) 2021-07-06
AU2022256212A1 (en) 2022-12-08
CL2021001316A1 (es) 2021-10-29
MD4851B1 (ro) 2023-04-30
CN113164464A (zh) 2021-07-23
EP4218758A3 (en) 2023-08-23
CN114652721A (zh) 2022-06-24
MD4844B1 (ro) 2023-02-28
MD4844C1 (ro) 2023-09-30
WO2020106191A1 (ru) 2020-05-28
US20220362230A1 (en) 2022-11-17
EP3884945A4 (en) 2022-11-23
CA3120882A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2023010326A (es) Inhibidores de atf6 y sus usos.
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX392259B (es) ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a
NZ759295A (en) 5-5 fused rings as c5a inhibitors
CY1106371T1 (el) Μεθοδοι αγωγης της σχιζοφρενειας
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MD20160102A2 (ro) Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
DK3956310T3 (da) Modificerede aminosyrederivater til behandling af neurologiske sygdomme og udvalgte psykiatriske lidelser
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2022013503A (es) Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.
EA202191812A1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
WO2022093552A8 (en) Rev-erb agonists
LT4118069T (lt) Parahidrochinono dariniai, tokie kaip vegf, tnf ir (arba) il inhibitoriai, skirti uždegiminėms nervų sistemos ligoms gydyti
EP3936184A4 (en) ELECTRICAL STIMULATION THERAPY ELECTRODE AND ELECTRICAL STIMULATION THERAPY DEVICE
GB201904374D0 (en) Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
EA201992341A8 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
KR102272756B9 (ko) 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법
JOP20200104B1 (ar) مركبات مثبطة لـ btk
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.